MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, MTNB had -$3,285K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$3,285K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Gross proceeds from private plac...
    • Change in fair value of warrant ...
    • Prepaid expenses and other curre...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Accrued expenses and other liabi...
    • Operating lease liabilities
    • Others

Cash Flow
2025-12-31
Amortization of bond premium
0
Impairment charges of goodwill and other intangible assets
0
Impairment charges of other assets
0
Income tax benefit
0
Depreciation and amortization
32
Net gain on disposal of assets
37
Loss on operating lease right-of-use assets modification
241
Prepaid expenses and other current assets
-665
Accounts payable
220
Accrued expenses and other liabilities
-1,353
Operating lease liabilities
-1,042
Net loss
-10,345
Change in fair value of warrant liability
3,161
Amortization of operating lease right-of-use assets
420
Amortization of finance lease right-of-use assets
4
Stock-based compensation expense
1,023
Net cash used in operating activities
-7,011
Purchases of marketable debt securities
0
Proceeds from sales of marketable debt securities
0
Proceeds from sale of assets
335
Net cash provided by investing activities
335
Net proceeds from public offerings of common stock and warrants
0
Gross proceeds from private placement of preferred stock and common stock warrants
3,300
Transaction costs paid pursuant to private placement
29
Net proceeds from exercise of warrants
129
Payments of capital lease liability principal
9
Net cash provided by financing activities
3,391
Net (decrease)/increase in cash, cash equivalents and restricted cash
-3,285
Net (decrease)/increase in cash, cash equivalents and restricted cash
-3,285
Cash, cash equivalents and restricted cash at beginning of period
7,534
Cash, cash equivalents and restricted cash at end of period
4,249
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Gross proceeds fromprivate placement of...$3,300K Net proceeds fromexercise of warrants$129K Proceeds from sale ofassets$335K Net(decrease)/increase in cash, cash...-$3,285K Net cash provided byfinancing activities$3,391K Net cash provided byinvesting activities$335K Canceled cashflow$38K Net(decrease)/increase in cash, cash...-$3,285K Canceled cashflow$3,726K Change in fair value ofwarrant liability$3,161K Stock-based compensationexpense$1,023K Prepaid expenses andother current assets-$665K Amortization of operatinglease right-of-use...$420K Loss on operatinglease right-of-use...$241K Accounts payable$220K Depreciation andamortization$32K Amortization of finance leaseright-of-use assets$4K Transaction costs paidpursuant to private...$29K Payments of capital leaseliability principal$9K Net cash used inoperating activities-$7,011K Canceled cashflow$5,766K Net loss-$10,345K Accrued expenses andother liabilities-$1,353K Operating leaseliabilities-$1,042K Net gain on disposalof assets$37K

Matinas BioPharma Holdings, Inc. (MTNB)

Matinas BioPharma Holdings, Inc. (MTNB)